Covid 19 Clinical Trials

	Name (Synonyms)	Correlation
drug1849	Placebo on a 0- and 14-day schedule Wiki	1.00
drug1380	Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki	1.00
drug1457	Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki	1.00
drug1057	High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki	1.00
drug1381	Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki	0.71
drug1058	High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki	0.71
drug1850	Placebo on a 0- and 28-day schedule Wiki	0.71
drug1458	Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki	0.71
drug1822	Placebo Wiki	0.06

Correlated MeSH Terms (2)

	Name (Synonyms)	Correlation
D003141	Communicable Diseases NIH	0.09
D007239	Infection NIH	0.06

Correlated HPO Terms (0)

	Name (Synonyms)	Correlation

There is one clinical trial.

Clinical Trials

1 Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)

This study is a phase II, parallel, prospective, randomized, double-blind, placebo controlled trial. The present study will aim to address the efficacy and safety of acute administration of triiodothyronine on ICU patients diagnosed with pulmonary infection due to COVID-19 and require mechanical respiratory support or ECMO.

NCT04348513 Pulmonary Infection Covid-19 Drug: T3 solution for injection Drug: Placebo

MeSH:Infection Communicable Diseases

Primary Outcomes

Description: The primary objective of the study is to determine whether the administration of intravenous triiodothyronine in ICU patients diagnosed with pulmonary infection due to COVID-19 facilitates weaning from cardiorespiratory support compared to placebo. Successful weaning is defined as no requirement for ventilatory support after extubation (mechanical support) or support from ECMO for 48 hours. The primary objective will be measured as percentage of patients successfully weaned after 30 days of follow-up.

Measure: Assessment of weaning from cardiorespiratory support

Time: 30 days

Secondary Outcomes

Description: Hemodynamic status will be assessed by continuous blood pressure measurements (systolic BP in mmHg)

Measure: Assessment of hemodynamic status

Time: 30 days

Description: Hemodynamic status will be assessed by continuous blood pressure measurements (diastolic BP in mmHg)

Measure: Assessment of hemodynamic status

Time: 30 days

Description: Hemodynamic status will be assessed by continuous blood pressure measurements (mean BP in mmHg)

Measure: Assessment of hemodynamic status

Time: 30 days

Description: Hemodynamic status will be assessed by the number of participants with use of inotropic and vasoactive drugs

Measure: Assessment of hemodynamic status

Time: 30 days

Description: Pulmonary function will be assessed by arterial measurement of blood gases (arterial partial pressure of oxygen in mmHg)

Measure: Assessment of pulmonary function

Time: 30 days

Description: Pulmonary function will be assessed by arterial measurement of blood gases (arterial partial pressure of carbon dioxide in mmHg)

Measure: Assessment of pulmonary function

Time: 30 days

Description: Pulmonary function will be assessed by arterial measurement of lactate levels (in mmol/L)

Measure: Assessment of pulmonary function

Time: 30 days

Description: Hepatic function will be assessed by laboratory measurements in blood. Changes in aspartate aminotransferase (AST in IU/L) will be measured.